LISBON, Portugal—Five years ago, the chair of the EXCEL trial surgical committee stood on stage at the 2019 European Association for Cardio-Thoracic Surgery (EACTS) meeting and accused the trial’s ...
Madrid, Spain – 29 August 2025: Updated ESC/EACTS Guidelines, being published today at ESC Congress 2025, aim to improve the way that patients with valvular heart disease are diagnosed and treated, ...
Leading heart failure specialist features tecarfarin data and Cadrenal's proposed clinical trial protocol at 8th EACTS Mechanical Circulatory Support Summit Dr. Mehra, who also chaired Abbott's ...
The Nature Index tracks primary research articles from 145 natural-science and health-science journals, chosen based on reputation by an independent group of researchers. The Nature Index provides ...
PONTE VEDRA, Fla., Nov. 12, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a late-stage biopharmaceutical company developing tecarfarin, a new vitamin K antagonist (VKA) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results